arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

Cronos Group Inc.

CRON
$3.09 ▲ +0.03 (+0.98%) at close
Materials ·Medicinal Chemicals & Botanical Products ·USMedicinal Chemicals & Botanical Products
30 Visible periods
28 Metrics
Peer-ranked Benchmarks
Price Chart
30
Health
Poor
Bearish
auto_awesome

Analytical Summary

Cronos Group Inc. faces fundamental challenges with weakness in Profit Margin (%) and Operating Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $1.2B
Dividend Yield
Revenue Growth 40.1%
Op. Margin -4.1%
ROIC -0.1%
FCF / Share $0.02
Trailing P/E 77.3x
Price / Book 1.1x
FCF Yield 0.8%
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

30-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$45.21M
↑ +40.1%
Net Income Profit after all expenses
$13.75M
↑ +124.6%
Operating Margin Operating profit as % of sales
-4.1%
↑ +75.9% 14th
FCF / Share Free cash flow per share
$0.02
↑ +3.2%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile

Health Breakdown

Profitability
20
Returns
43
Cash Quality
21

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 8 years · 30 quarters